Availability and affordability of treatment for human african trypanosomiasis

Tropical Medicine and International Health

Volumn 6, Issue 11, 2001, Pages 957-959

  Gastellu Etchegorry, M ^a   Helenport, J P ^b   Pecoul, B ^a   Jannin, J ^c   Legros, D ^d  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Rhône Poulenc Rorer International SA ^*  (France)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d EPICENTRE   (France)

Author keywords

Distribution strategy; HAT pharmaceuticals; Human African Trypanosomiasis (HAT)

Indexed keywords

2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; DIMINAZENE ACETURATE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE ISETHIONATE; SURAMIN;

DISEASE TREATMENT; DRUG PRESCRIBING; DRUG RESISTANCE; TRYPANOSOMIASIS;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESEARCH; HUMAN; NON PROFIT ORGANIZATION; TRYPANOSOMIASIS; WORLD HEALTH ORGANIZATION;

EFLORNITHINE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MELARSOPROL; PENTAMIDINE; RESEARCH; SURAMIN; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN; WORLD HEALTH ORGANIZATION;

PROTOZOA;

EID: 0034780953     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2001.00764.x     Document Type: Article

References (4)

1. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: A randomised trial
2. Echecs therapeutiques du melarsoprol parmi des patients traites au stade tardif de trypanosomiase humaine africaine a T.b. gambiense en ouganda